Home  |  Contact

UniProtKB/Swiss-Prot P03950: Variant p.Lys41Ile

Angiogenin
Gene: ANG
Variant information

Variant position:  41
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Lysine (K) to Isoleucine (I) at position 41 (K41I, p.Lys41Ile).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (K) to medium size and hydrophobic (I)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Amyotrophic lateral sclerosis 9 (ALS9) [MIM:611895]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. {ECO:0000269|PubMed:15557516, ECO:0000269|PubMed:16501576, ECO:0000269|PubMed:17703939, ECO:0000269|PubMed:17886298, ECO:0000269|PubMed:17900154, ECO:0000269|PubMed:18087731, ECO:0000269|PubMed:22292843, ECO:0000269|PubMed:25372031}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In ALS9; loss of angiogenic activity; reduced ribonucleolytic activity; retains nuclear translocation.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  41
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  147
The length of the canonical sequence.

Location on the sequence:   PTLAQDNSRYTHFLTQHYDA  K PQGRDDRYCESIMRRRGLTS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 25 – 147 Angiogenin
Active site 37 – 37 Proton acceptor
Modified residue 25 – 25 Pyrrolidone carboxylic acid
Mutagenesis 29 – 29 R -> A. Significantly decreases binding affinity for RNH1.
Mutagenesis 32 – 32 H -> A. Significantly decreases binding affinity for RNH1.
Mutagenesis 36 – 36 Q -> A. Slightly decreases binding affinity for RNH1.
Mutagenesis 59 – 59 L -> P. Homodimerization is similar to wild-type; causes mislocalization in the cytoplasm; reduces strongly ribonucleolytic activity.


Literature citations

ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis.
Greenway M.J.; Andersen P.M.; Russ C.; Ennis S.; Cashman S.; Donaghy C.; Patterson V.; Swingler R.; Kieran D.; Prehn J.; Morrison K.E.; Green A.; Acharya K.R.; Brown R.H. Jr.; Hardiman O.;
Nat. Genet. 38:411-413(2006)
Cited for: VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63 AND ILE-64; VARIANT VAL-70;

Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis.
Wu D.; Yu W.; Kishikawa H.; Folkerth R.D.; Iafrate A.J.; Shen Y.; Xin W.; Sims K.; Hu G.-F.;
Ann. Neurol. 62:609-617(2007)
Cited for: VARIANTS ALS9 SER-20; ILE-41; ASN-52 AND LEU-136; CHARACTERIZATION OF VARIANTS ALS9 ILE-41; ASN-52 AND LEU-136; TISSUE SPECIFICITY;

Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis.
Crabtree B.; Thiyagarajan N.; Prior S.H.; Wilson P.; Iyer S.; Ferns T.; Shapiro R.; Brew K.; Subramanian V.; Acharya K.R.;
Biochemistry 46:11810-11818(2007)
Cited for: CHARACTERIZATION OF VARIANTS ALS9 LEU-36; ILE-41; GLU-41; LYS-55; TRP-63 AND ILE-64; CHARACTERIZATION OF VARIANT VAL-70;

SOD1, ANG, TARDBP and FUS mutations in amyotrophic lateral sclerosis: a United States clinical testing lab experience.
Brown J.A.; Min J.; Staropoli J.F.; Collin E.; Bi S.; Feng X.; Barone R.; Cao Y.; O'Malley L.; Xin W.; Mullen T.E.; Sims K.B.;
Amyotroph. Lateral Scler. 13:217-222(2012)
Cited for: VARIANTS ALS9 HIS-38; ILE-41 AND GLY-46;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.